doxazosin has been researched along with Lower Urinary Tract Symptom in 27 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized controlled trial, 55 sexually active lower urinary tract symptoms/benign prostatic obstruction patients with concomitant erectile dysfunction were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second received tolterodine 4 mg plus doxazosin 2 mg (tolterodine group) for 12 weeks." | 9.51 | Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. ( El-Assmy, A; Elbaz, R; Hashem, A; Shokeir, AA; Zahran, MH, 2022) |
| "We examined the effects of doxazosin, finasteride and combined therapy in men with lower urinary tract symptoms associated with benign prostatic hyperplasia on sexual function, as assessed by the Brief Male Sexual Function Inventory during 4 years." | 9.19 | Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. ( Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT, 2014) |
| "We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS)." | 9.19 | Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial. ( Çelik, O; Eryıldırım, B; Faydacı, G; Tarhan, F; Tosun, Ç, 2014) |
| "We examined the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 (Medical Outcomes Study Short-Form 36) and 2 disease specific instruments (BII, benign prostatic hyperplasia Impact Index and I-PSS-QoL, International Prostate Symptom Score-QoL) during 4 years." | 9.17 | Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. ( Eggers, PW; Fwu, CW; Kaplan, SA; Kirkali, Z; Kusek, JW; Lee, JY, 2013) |
| "To investigate the safety of daily coadministration of α-blockers with tadalafil 5 mg in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia." | 9.16 | Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. ( Brady, E; Clark, WR; Dgetluck, N; Goldfischer, E; Klise, SR; Kowalczyk, JJ; Shane, MA, 2012) |
| "To compare the rapidity of improvement in lower urinary tract symptoms (LUTS) for the doxazosin gastrointestinal therapeutic system (GITS) and tamsulosin in benign prostatic hyperplasia (BPH) patients." | 9.15 | Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. ( Chung, BH; Chung, MS; Lee, SH; Park, KK; Yoo, SJ, 2011) |
| "This meta-analysis indicates that doxazosin-GITS has significantly higher efficacy and lower AEs than tamsulosin in patients with lower urinary tract symptoms/benign prostate hyperplasia." | 9.12 | Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis. ( Guo, J; Tang, R, 2021) |
| "In this randomized controlled trial, 55 sexually active lower urinary tract symptoms/benign prostatic obstruction patients with concomitant erectile dysfunction were randomly allocated in two groups: the first received mirabegron 50 mg plus doxazosin 2 mg once daily (mirabegron group) and the second received tolterodine 4 mg plus doxazosin 2 mg (tolterodine group) for 12 weeks." | 5.51 | Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial. ( El-Assmy, A; Elbaz, R; Hashem, A; Shokeir, AA; Zahran, MH, 2022) |
| "Medications targeting androgen receptor activity (eg finasteride) or smooth muscle contractility (eg doxazosin) do not resolve lower urinary tract symptoms indicative of lower urinary tract dysfunction in an important subgroup of men." | 5.30 | Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. ( Leverson, GE; Macoska, JA; McVary, KT; Ricke, WA; Uchtmann, KS, 2019) |
| " Doxazosin in the management of arterial hypertension was associated with a higher risk of cardiovascular disease, particularly heart failure, than chlorthalidone." | 5.22 | Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. ( Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022) |
| "We examined the effects of doxazosin, finasteride and combined therapy in men with lower urinary tract symptoms associated with benign prostatic hyperplasia on sexual function, as assessed by the Brief Male Sexual Function Inventory during 4 years." | 5.19 | Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. ( Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT, 2014) |
| "We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS)." | 5.19 | Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial. ( Çelik, O; Eryıldırım, B; Faydacı, G; Tarhan, F; Tosun, Ç, 2014) |
| "To evaluate predictors of the response to doxazosin, a selective alpha-adrenoceptor antagonist, when used for the treatment of lower urinary tract symptoms in men with Parkinson's disease." | 5.19 | Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease. ( Barbosa, ER; Bessa Junior, Jd; Bruschini, H; Gomes, CM; Lopes, RI; Nitti, VW; Sallem, FS; Sammour, ZM; Srougi, M; Trigo-Rocha, FE, 2014) |
| "We examined the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia on quality of life assessed with MOS-SF-36 (Medical Outcomes Study Short-Form 36) and 2 disease specific instruments (BII, benign prostatic hyperplasia Impact Index and I-PSS-QoL, International Prostate Symptom Score-QoL) during 4 years." | 5.17 | Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. ( Eggers, PW; Fwu, CW; Kaplan, SA; Kirkali, Z; Kusek, JW; Lee, JY, 2013) |
| "To investigate the safety of daily coadministration of α-blockers with tadalafil 5 mg in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia." | 5.16 | Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. ( Brady, E; Clark, WR; Dgetluck, N; Goldfischer, E; Klise, SR; Kowalczyk, JJ; Shane, MA, 2012) |
| "To compare the rapidity of improvement in lower urinary tract symptoms (LUTS) for the doxazosin gastrointestinal therapeutic system (GITS) and tamsulosin in benign prostatic hyperplasia (BPH) patients." | 5.15 | Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. ( Chung, BH; Chung, MS; Lee, SH; Park, KK; Yoo, SJ, 2011) |
| "This meta-analysis indicates that doxazosin-GITS has significantly higher efficacy and lower AEs than tamsulosin in patients with lower urinary tract symptoms/benign prostate hyperplasia." | 5.12 | Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis. ( Guo, J; Tang, R, 2021) |
| "Male lower urinary tract symptoms have been correlated with an increased risk of death; however, it is unclear if treatment will reduce this risk." | 3.30 | The Reduction of Male Lower Urinary Tract Symptoms Is Associated With a Decreased Risk of Death. ( McClure, JA; Welk, B, 2023) |
| "Several drugs, currently used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), can be associated with bothersome sexual side effects, including ejaculatory dysfunction (EjD)." | 2.50 | Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. ( Carini, M; Corona, G; Ficarra, V; Gacci, M; Maggi, M; Novara, G; Sebastianelli, A; Serni, S; Shariat, SF; Zattoni, F, 2014) |
| " Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy." | 1.62 | Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. ( Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC, 2021) |
| "Williams-Beuren syndrome is a chromosomal disorder caused by a deletion at region 7q11." | 1.62 | Longitudinal Improvement of Lower Urinary Tract Symptoms in Williams-Beuren Syndrome. ( Bruschini, H; de Bessa, J; Gomes, CM; Hisano, M; Nahas, WC; Sammour, ZM; Srougi, M, 2021) |
| "Doxazosin was safe and well tolerated." | 1.38 | Long-term safety, tolerability, and efficacy of α1-adrenergic blocker in young men with primary bladder neck obstruction: results from a single centre in China. ( Dong, C; Gao, W; Han, X; Jia, R; Li, B; Li, S; Xiao, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (77.78) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, SR | 1 |
| Walter, LC | 1 |
| Ensrud, KE | 1 |
| Suskind, AM | 1 |
| Newman, JC | 1 |
| Ricke, WA | 2 |
| Liu, TT | 1 |
| McVary, KT | 4 |
| Covinsky, K | 1 |
| Elbaz, R | 1 |
| El-Assmy, A | 1 |
| Zahran, MH | 1 |
| Hashem, A | 1 |
| Shokeir, AA | 1 |
| Mansbart, F | 1 |
| Kienberger, G | 1 |
| Sönnichsen, A | 1 |
| Mann, E | 1 |
| Welk, B | 1 |
| McClure, JA | 1 |
| Sammour, ZM | 2 |
| Hisano, M | 1 |
| de Bessa, J | 1 |
| Bruschini, H | 2 |
| Nahas, WC | 1 |
| Srougi, M | 2 |
| Gomes, CM | 2 |
| Guo, J | 1 |
| Tang, R | 1 |
| Lee, CL | 1 |
| Kuo, HC | 4 |
| Rogers, T | 1 |
| Mahon, J | 1 |
| Gupta, NK | 1 |
| Macoska, JA | 1 |
| Uchtmann, KS | 1 |
| Leverson, GE | 1 |
| Lee, YC | 2 |
| Liu, CC | 2 |
| Juan, YS | 2 |
| Wu, WJ | 2 |
| Li, WM | 1 |
| Yeh, HC | 1 |
| Wang, CJ | 2 |
| Huang, CN | 2 |
| Huang, CH | 1 |
| Huang, SP | 2 |
| Araki, T | 1 |
| Monden, K | 1 |
| Araki, M | 1 |
| Jhang, JF | 1 |
| Jiang, YH | 2 |
| Lin, VC | 1 |
| Liao, CH | 2 |
| Zisman, A | 1 |
| Fwu, CW | 2 |
| Eggers, PW | 2 |
| Kirkali, Z | 2 |
| Burrows, PK | 1 |
| Kusek, JW | 2 |
| Tarhan, F | 1 |
| Çelik, O | 1 |
| Tosun, Ç | 1 |
| Faydacı, G | 1 |
| Eryıldırım, B | 1 |
| Gacci, M | 1 |
| Ficarra, V | 1 |
| Sebastianelli, A | 1 |
| Corona, G | 1 |
| Serni, S | 1 |
| Shariat, SF | 1 |
| Maggi, M | 1 |
| Zattoni, F | 1 |
| Carini, M | 1 |
| Novara, G | 1 |
| Bessa Junior, Jd | 1 |
| Barbosa, ER | 1 |
| Lopes, RI | 1 |
| Sallem, FS | 1 |
| Trigo-Rocha, FE | 1 |
| Nitti, VW | 1 |
| Kaplan, SA | 2 |
| Bao, BY | 1 |
| Belayneh, M | 1 |
| Korownyk, C | 1 |
| Chung, MS | 1 |
| Lee, SH | 1 |
| Park, KK | 1 |
| Yoo, SJ | 1 |
| Chung, BH | 1 |
| Li, B | 1 |
| Gao, W | 1 |
| Dong, C | 1 |
| Han, X | 1 |
| Li, S | 1 |
| Jia, R | 1 |
| Xiao, C | 1 |
| Goldfischer, E | 1 |
| Kowalczyk, JJ | 1 |
| Clark, WR | 1 |
| Brady, E | 1 |
| Shane, MA | 1 |
| Dgetluck, N | 1 |
| Klise, SR | 1 |
| Osman, NI | 1 |
| Chapple, CR | 1 |
| Lee, JY | 1 |
4 reviews available for doxazosin and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents | 2022 |
Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis.
Topics: Doxazosin; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tamsulosin; Treatment | 2021 |
Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutasteride; Ejaculation; Finasteri | 2014 |
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptom | 2016 |
13 trials available for doxazosin and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.
Topics: Acetanilides; Doxazosin; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic | 2022 |
The Reduction of Male Lower Urinary Tract Symptoms Is Associated With a Decreased Risk of Death.
Topics: Doxazosin; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Pelvis; Prostate | 2023 |
Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; | 2018 |
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Biopsy; Cohort Studies; Disea | 2019 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazos | 2013 |
Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biopsy; Celecoxib; Cyclooxygenase 2 Inhibitors | 2013 |
Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Azasteroids; Disease Pr | 2014 |
Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Disease Progression; Dose-Res | 2014 |
Comparison of the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia: a randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Drug Administration Schedule; Humans; Isos | 2014 |
Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Antiparkinson Agents; Doxazosin; Humans; Lower | 2014 |
Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Humans; Lower Urinary Tract Symptoms; Male; Midd | 2011 |
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carbolines; Double-Blind Method; Doxazosin; Hemodynam | 2012 |
Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia.
Topics: Administration, Oral; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Met | 2013 |
10 other studies available for doxazosin and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
Topics: Aged; Aged, 80 and over; Disease Progression; Doxazosin; Drug Therapy, Combination; Drug-Related Sid | 2021 |
Longitudinal Improvement of Lower Urinary Tract Symptoms in Williams-Beuren Syndrome.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Child; Doxazosin; Female; Follow-Up Studies; Hu | 2021 |
Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Humans; Lower Urinary Tract Symptoms; Male | 2018 |
The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Humans; Lower Ur | 2013 |
Editorial comment.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutas | 2014 |
How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.
Topics: Azasteroids; Doxazosin; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prost | 2014 |
Re: Comparison of the Efficacy of Isosorbide Mononitrate and Doxazosin in the Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: A Randomized Clinical Trial.
Topics: Doxazosin; Humans; Isosorbide Dinitrate; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia | 2015 |
The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Humans; Lower Ur | 2016 |
Long-term safety, tolerability, and efficacy of α1-adrenergic blocker in young men with primary bladder neck obstruction: results from a single centre in China.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; China; Doxazosin; Humans; Lower Urinary | 2012 |
Lower urinary tract symptoms revisited.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Benzhydryl Compounds; Cresols; Cystitis, Inter | 2012 |